Evaluating Intervention Points in the Complement Cascade to Achieve & Improve Efficacy & Advance the Next Generation of Inhibitors for Inflammatory Diseases
Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com.
The 8th Complement-based Drug Development Summit
In 2024, the complement community was shifting gear, with more companies than ever targeting alternative complement proteins for their therapies, allowing for a larger range of diseases to be targeted.
With more assets in ophthalmology, neurology, and oncology than ever before, the complement-based therapeutics field had everyone asking the same question: which inhibitor would be the next to harness the complement system for the development of groundbreaking therapies?
From the discovery of new pathways to target to post-approval indication expansion, the immunology landscape was primed to capitalize on the huge strides being taken in achieving efficacy and approving the safety profile of complement-based therapeutics.
Attendees joined 100+ complement industry leaders, scientists, and clinicians at the premier, end-to-end 8th Complement-Based Drug Development Summit, and so helped to shape the future of complement-targeted therapies.
World-Class Speaker Faculty Included:
James Hamilton
Senior Vice President & Chief - Discovery & Translational Medicine Development
Arrowhead Pharmaceuticals, Inc.
Companies Who Attended:
2024 Partners:
